Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 13/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.31 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.31 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4174856 | 0.96 | PIK3CD (0.45) | PIK3CDTRPA1KDRTTBK1TTBK2 | |
| SCHEMBL4181122 | 0.81 | PIK3CD (0.54) | PIK3CD | |
| SCHEMBL4563890 | 0.73 | PIK3CD (0.49) | PIK3CDTRPA1 | |
| SCHEMBL21705927 | 0.70 | PIK3CD (0.58) | PIK3CD | |
| SCHEMBL4178472 | 0.68 | PIK3CD (0.49) | PIK3CDTRPA1KDRDYRK1B | |
| SCHEMBL12005060 | 0.68 | JAK2 (0.43) | PIK3CDTRPA1KDRTTBK1TTBK2 | |
| SCHEMBL10250927 | 0.66 | PIK3CD (0.65) | PIK3CD | |
| SCHEMBL17971305 | 0.66 | DRD4 (0.41) | PIK3CDKDR | |
| SCHEMBL4176627 | 0.66 | PIK3CD (0.68) | PIK3CD | |
| SCHEMBL4184462 | 0.65 | PIK3CD (0.47) | PIK3CDTRPA1KDRDYRK1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200048265-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2020-02-13 | — | — | US | disclosed |
| EP-2137186-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | Amgen Inc. (US) | 2009-12-30 | — | — | EP | disclosed |
| WO-2008118468-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200048265-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | PIK3CD 16/4885TRPA1 2403/4885KDR 1583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.